RNA, U6atac small nuclearGenealiases: MEJINS · RNU6ATAC1 · U6ATAC
Q-omics provides the consensus-scored RNU6ATAC profile across patient tissues and cancer cell-line models. RNU6ATAC expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RNU6ATAC is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, RNU6ATAC RNA expression shows 7,971 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, COAD, and ACC as cancer lineages where RNU6ATAC shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU6ATAC — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU6ATAC survival associations across molecular data types. RNU6ATAC RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU6ATAC RNA expression–survival associations across cancer types. High RNU6ATAC expression shows unfavorable associations in KIRC, MESO, ACC, BRCA, KIRP and LIHC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RNU6ATAC RNA expression.
This table summarizes RNU6ATAC tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for RNU6ATAC. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU6ATAC shows lower tumor expression in THCA and KICH and higher tumor expression in COAD, LUAD, HNSC and LUSC. The COAD box plot shows higher RNU6ATAC RNA expression in tumor versus normal tissue (log2 FC = +0.861, t-test p < 0.001).
This table shows molecular features associated with RNU6ATAC in patient tissues and cancer cell lines. In patient samples, RNU6ATAC shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
